Two years of adjuvant tamoxifen provides a survival benefit compared with no systemic treatment in premenopausal patients with primary breast cancer: Long-Term follow-up (> 25 years) of the phase III SBII:2pre trial

Maria Ekholm, Pär Ola Bendahl, Mårten Fernö, Bo Nordenskjöld, Olle Stål, Lisa Rydén

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskriftPeer review

20 !!Citations (SciVal)

Sökresultat